Celldex Therapeutics (NASDAQ: CLDX) reported Q1 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $406 thousand versus the consensus estimate of $460 thousand.

For earnings history and earnings-related data on (CLDX) click here.